Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) (MSCIMS)
This study has been completed.
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust
Medical Research Council
Information provided by (Responsible Party):
Peter Connick, University of Cambridge
First received: November 1, 2006
Last updated: October 22, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10.